				Détail des votes 2023		
Issuer Name	Meeting Date	Country	Proposal Number	Dronosal Tayt	Vote Instruction	Vote Against Mgmt
Actia Group	05/23/2023	France	1	Approve Financial Statements and Statutory Reports	For	No
Actia Group	05/23/2023	France	2	Approve Consolidated Financial Statements and Statutory Reports	1	No
Actia Group	05/23/2023	France	3	Approve Allocation of Income and Dividends of EUR 0.12 per Share		No
Actia Group	05/23/2023	France	4	Approve Transaction with LP2C Re: Services Agreement		Yes
Actia Group Actia Group	05/23/2023 05/23/2023	France France	5	Approve Auditors' Special Report on Related-Party Transactions Approve Auditors' Special Report on Related-Party Transactions		No No
Actia Group	05/23/2023	France	7	Approve Remuneration of Directors in the Aggregate Amount of EUR 40,000 Authorize Repurchase of Up to 2 Percent of Issued Share Capital		No
Actia Group	05/23/2023	France	8	Authorize Trigorian do Company		No
Allianz SE	05/04/2023	Germany	2	Approve Allocation of Income and Dividends of EUR 11.40 per Share		No
Allianz SE	05/04/2023	Germany	3.1	Approve Discharge of Management Board Member Oliver Baete for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	3.2	Approve Discharge of Management Board Member Sergio Balbinot for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	3.3	Approve Discharge of Management Board Member Sirma Boshnakova for Fiscal Year 2022		No
Allianz SE Allianz SE	05/04/2023 05/04/2023	Germany	3.4 3.5	Approve Discharge of Management Board Member Barbara Karuth-Zelle for Fiscal Year 2022 Approve Discharge of Management Board Member Klaus-Peter Roehler for Fiscal Year 2022		No No
Allianz SE	05/04/2023	Germany	3.6	Approve Discharge on Management Board Member Ivan de la Sota for Fiscal Year 2022 Approve Discharge of Management Board Member Ivan de la Sota for Fiscal Year 2022  September 1		No
Allianz SE	05/04/2023	Germany	3.7	Approve Discharge of Management Board Member Giulio Terzariol for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	3.8	Approve Discharge of Management Board Member Guenther Thallinger for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	3.9	Approve Discharge of Management Board Member Christopher Townsend for Fiscal Year 2022	1 01	No
Allianz SE	05/04/2023	Germany	3.10	Approve Discharge of Management Board Member Renate Wagner for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	3.11	Approve Discharge of Management Board Member Andreas Wimmer for Fiscal Year 2022		No
Allianz SE Allianz SE	05/04/2023 05/04/2023	Germany	4.1	Approve Discharge of Supervisory Board Member Michael Diekmann for Fiscal Year 2022		No No
Allianz SE Allianz SE	05/04/2023	Germany Germany	4.2	Approve Discharge of Supervisory Board Member Gabriele Burkhardt-Berg for Fiscal Year 2022 Approve Discharge of Supervisory Board Member Herbert Hainer for Fiscal Year 2022		No No
Allianz SE	05/04/2023	Germany	4.4	Approve Discharge of Supervisory Board wember herbert haliner for Fiscal Tear 2022  Approve Discharge of Supervisory Board Member Sophie Boissard for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	4.5	Approve bisuriarge of Supervisory Board Member Chairles Bosse for Fiscal Year 2022  Approve Discharge of Supervisory Board Member Chairles Bosse for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	4.6	Approve Discharge of Supervisory Board Member Rashmy Chatterjee for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	4.7	Approve Discharge of Supervisory Board Member Friedrich Eichiner for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	4.8	Approve Discharge of Supervisory Board Member Jean-Claude Le Goaer for Fiscal Year 2022	For	No
Allianz SE	05/04/2023	Germany	4.9	Approve Discharge of Supervisory Board Member Martina Grundler for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	4.10	Approve Discharge of Supervisory Board Member Godfrey Hayward for Fiscal Year 2022		No
Allianz SE	05/04/2023	Germany	4.11	Approve Discharge of Supervisory Board Member Frank Kirsch for Fiscal Year 2022		No No
Allianz SE Allianz SE	05/04/2023 05/04/2023	Germany	4.12	Approve Discharge of Supervisory Board Member Juergen Lawrenz for Fiscal Year 2022 Approve Discharge of Supervisory Board Member Primina Di Paolo for Fiscal Year 2022		No.
Allianz SE	05/04/2023	Germany	4.14	Approve Discharge of Supervisory Board Member Jim Hacemann Snabe for Fiscal Year 2022	1	No.
Allianz SE	05/04/2023	Germany	5	Ratify PricewaterhouseCoopers GmbH as Auditors for Fiscal Year 2023 and for the Review of Interim Financial Statements for the First Half of Fiscal Year 2023	For	No
Allianz SE	05/04/2023	Germany	6	Approve Remuneration Report	For	No
Allianz SE	05/04/2023	Germany	7	Approve Remuneration of Supervisory Board		No
Allianz SE	05/04/2023	Germany	8	Approve Virtual-Only Shareholder Meetings Until 2025		No
Allianz SE	05/04/2023	Germany	9	Amend Articles Re: Participation of Supervisory Board Members in the Annual General Meeting by Means of Audio and Video Transmission		No
Allianz SE Amazon.com. Inc.	05/04/2023	Germany USA	10 1a	Amend Article Re: Location of Annual Meeting Fleed Director, Jeffrey P. Bezos		No Yes
Amazon.com, Inc. Amazon.com. Inc.	05/24/2023	USA	1b	Elect Director Jamery P. Bezos Elect Director Andrew R. Jassy		No Yes
Amazon.com, Inc.	05/24/2023	USA	10	Elect Director Keith B. Alexander		No
Amazon.com, Inc.	05/24/2023	USA	1d	Elect Director Edith W. Cooper	Against	Yes
Amazon.com, Inc.	05/24/2023	USA	1e	Elect Director Jamie S. Gorelick		Yes
Amazon.com, Inc.	05/24/2023	USA	1f	Elect Director Daniel P. Huttenlocher		Yes
Amazon.com, Inc.	05/24/2023	USA	1g	Elect Director Judith A. McGrath		Yes
Amazon.com, Inc.		USA	1h	Elect Director Indra K. Nooyi	1	No
Amazon.com, Inc. Amazon.com, Inc.	05/24/2023 05/24/2023	USA	1i 1i	Elect Director Jonathan J. Rubinstein Elect Director Patricia Q. Stonesifer		Yes Yes
Amazon.com, Inc.	05/24/2023	USA	1k	Lieu Cinecuti ramiala d. Sioniesirei Elect Directi ramiala d. Sioniesirei		No
Amazon.com, Inc.	05/24/2023	USA	2	Ratify Ratification of Emst & Young LLP as Auditors		No
Amazon.com, Inc.	05/24/2023	USA	3	Advisory Vote to Ratify Named Executive Officers' Compensation		Yes
Amazon.com, Inc.	05/24/2023	USA	4	Advisory Vote on Say on Pay Frequency	One Year	No
Amazon.com, Inc.	05/24/2023	USA	5	Amend Omnibus Stock Plan		No
Amazon.com, Inc.	05/24/2023	USA	6	Report on Climate Risk in Retirement Plan Options		Yes
Amazon.com, Inc.	05/24/2023	USA	7	Report on Customer Due Diligence		Yes
Amazon.com, Inc. Amazon.com, Inc.	05/24/2023 05/24/2023	USA	8	Revise Transparency Report to Provide Greater Disclosure on Government Requests Report on Government Take Down Requests		Yes No
Amazon.com, Inc.		USA	10	Keport on Government Take Down Requests Report on Impact of Climate Change Strategy Consistent With Just Transition Guidelines		Yes
Amazon.com, Inc.	05/24/2023	USA	11	Neport of Impact of Climate Unlarge distancy Consistent With Just Transparency Report		Yes
Amazon.com, Inc.	05/24/2023	USA	12	Report on Climate Lobbying		Yes
Amazon.com, Inc.	05/24/2023	USA	13	Report on Median and Adjusted Gender/Racial Pay Gaps	For	Yes
Amazon.com, Inc.	05/24/2023	USA	14	Report on Cost/Benefit Analysis of Diversity, Equity and Inclusion Programs		No
Amazon.com, Inc.	05/24/2023	USA	15	Amend Bylaws to Require Shareholder Approval of Certain Provisions Related to Director Nominations by Shareholders		No
Amazon.com, Inc.	05/24/2023	USA	16 17	Commission Third Party Assessment on Company's Commitment to Freedom of Association and Collective Bargaining		Yes
Amazon.com, Inc. Amazon.com, Inc.	05/24/2023 05/24/2023	USA	17	Consider Pay Disparity Between Executives and Other Employees Report on Animal Welfars Estandards		Yes Yes
Amazon.com, Inc.	05/24/2023	USA	19	KEPORT ON Animan weitare Standards Establish a Public Policy Committee	1	Yes
Amazon.com, Inc.	05/24/2023	USA	20	Adopt a Policy to Include Non-Management Employees as Prospective Director Candidates	1	Yes
Amazon.com, Inc.	05/24/2023	USA	21	Commission a Third Party Audit on Working Conditions		Yes
Amazon.com, Inc.	05/24/2023	USA	22	Report on Efforts to Reduce Plastic Use		Yes
Amazon.com, Inc.	05/24/2023	USA	23	Commission Third Party Study and Report on Risks Associated with Use of Rekognition		Yes
Apple Inc.	03/10/2023	USA	1a	Elect Director James Bell		No
Apple Inc.	03/10/2023	USA	1b	Elect Director Tim Cook		No
Apple Inc.	03/10/2023	USA	1c 1d	Elect Director Ale Gore Elect Director Alex Gorsky		Yes Yes
Apple Inc. Apple Inc.	03/10/2023 03/10/2023	USA	1d 1e	Elect Director Alex Goffsky   Elect Director Andrea Juno		Yes Yes
Apple Inc.	03/10/2023	USA	1f	Elect Director Art Levinson		No
Apple Inc.	03/10/2023	USA	1g	Lieu Director Morica Levinsoni Eleter Director Morica Levinson		No
Apple Inc.	03/10/2023	USA	1h	Elect Director Ron Sugar		No
Apple Inc.	03/10/2023	USA	1i	Elect Director Sue Wagner	Against	Yes

Apple Inc.         03/10/2023         USA         2         Ratify Ernst & Young LLP as Auditors           Apple Inc.         03/10/2023         USA         3         Advisory Vote to Ratify Named Executive Officers' Compensation           Apple Inc.         03/10/2023         USA         4         Advisory Vote on Say on Pay Frequency           Apple Inc.         03/10/2023         USA         5         Report on Civil Rights and Non-Discrimination Audit	For For	No No
Apple Inc.     03/10/2023     USA     3     Advisory Vote to Ratify Named Executive Officers' Compensation       Apple Inc.     03/10/2023     USA     4     Advisory Vote on Say on Pay Frequency	1.41	NI-
Apple Inc. 03/10/2023 USA 4 Advisory Vote on Say on Pay Frequency		INO
	One Year	No
	Against	No
Apple Inc. 03/10/2023 USA 6 Report on Operations in Communist China	Against	No
Apple Inc. 03/10/2023 USA 7 Adopt a Policy Establishing an Engagement Process with Proponents to Shareholder Pro	oposals For	Yes
Apple Inc. 03/10/2023 USA 8 Report on Median Gender/Racial Pay Gap	For	Yes
Apple Inc. 03/10/2023 USA 9 Amend Proxy Access Right	For	Yes
Bastide Le Confort Medical SA 12/13/2023 France 1 Approve Financial Statements and Discharge Directors	For	No
Bastide Le Confort Medical SA 12/13/2023 France 2 Approve Consolidated Financial Statements and Statutory Reports	For	No
Bastide Le Confort Medical SA 12/13/2023 France 3 Approve Non-Deductible Expenses	For	No
Bastide Le Confort Medical SA 12/13/2023 France 4 Approve Treatment of Losses	For	No
Bastide Le Confort Medical SA 12/13/2023 France 5 Acknowledge Auditors' Special Report on Related-Party Transactions	Against	Yes
Bastide Le Confort Medical SA 12/13/2023 France 6 Approve Transaction with SCI FDP NIMES Re: Commercial Leasing	Against	Yes
Bastide Le Confort Medical SA 12/13/2023 France 7 Approve Transaction with SCI BASTIDE RODEZ Re: Commercial Leasing	Against	Yes
Bastide Le Confort Medical SA 12/13/2023 France 8 Reelect Julie Caredda as Director	For	No
Bastide Le Confort Medical SA 12/13/2023 France 9 Reelect Kelly Guichard as Director	For	No
Bastide Le Confort Medical SA 12/13/2023 France 10 Reelect Robert Fabrega as Director	For	No
Bastide Le Confort Medical SA 12/13/2023 France 11 Acknowledge End of Mandate of Deloitte et Associes as Auditor and Decision Not to Rer	new For	No
Bastide Le Confort Medical SA 12/13/2023 France 12 Approve Compensation of Vincent Bastide, Chairman and CEO	For	No
Bastide Le Confort Medical SA 12/13/2023 France 13 Approve Compensation of Directors	For	No
Bastide Le Confort Medical SA 12/13/2023 France 14 Approve Compensation Report	For	No
Bastide Le Confort Medical SA   12/13/2023   France   15   Approve Remuneration Policy of Executive Corporate Officers	For	No
Bastide Le Confort Medical SA 12/13/2023 France 16 Approve Remuneration Policy of Directors	For	No
Bastide Le Confort Medical SA 12/13/2023 France 17 Authorize Filing of Required Documents/Other Formalities	For	No
Bastide Le Confort Medical SA 12/13/2023 France 18 Authorize Repurchase of Up to 10 Percent of Issued Share Capital	For	No
Bastide Le Confort Medical SA 12/13/2023 France 19 Authorize Decrease in Share Capital via Cancellation of Repurchased Shares	For	No
Bastide Le Confort Medical SA 12/13/2023 France 20 Authorize Filing of Required Documents/Other Formalities	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 2 Approve Allocation of Income and Dividends of EUR 8.50 per Ordinary Share and EUR 8	8.52 per Preferred Share For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 3 Approve Discharge of Management Board for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.1 Approve Discharge of Supervisory Board Member Norbert Reithofer for Fiscal Year 2022		No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.2 Approve Discharge of Supervisory Board Member Manfred Schoch for Fiscal Year 2022		No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.3 Approve Discharge of Supervisory Board Member Stefan Quandt for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.4 Approve Discharge of Supervisory Board Member Stefan Schmid for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.5 Approve Discharge of Supervisory Board Member Kurt Bock for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.6 Approve Discharge of Supervisory Board Member Christiane Benner for Fiscal Year 2023	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.7 Approve Discharge of Supervisory Board Member Marc Bitzer for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.8 Approve Discharge of Supervisory Board Member Bernhard Ebner for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.9 Approve Discharge of Supervisory Board Member Rachel Empey for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.10 Approve Discharge of Supervisory Board Member Heinrich Hiesinger for Fiscal Year 202	For For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.11 Approve Discharge of Supervisory Board Member Johann Horn for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.12 Approve Discharge of Supervisory Board Member Susanne Klatten for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.13 Approve Discharge of Supervisory Board Member Jens Koehler for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.14 Approve Discharge of Supervisory Board Member Gerhard Kurz for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.15 Approve Discharge of Supervisory Board Member Andre Mandl for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.16 Approve Discharge of Supervisory Board Member Dominique Mohabeer for Fiscal Year 2	2022 For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.17 Approve Discharge of Supervisory Board Member Anke Schaeferkordt for Fiscal Year 20	D22 For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.18 Approve Discharge of Supervisory Board Member Christoph Schmidt for Fiscal Year 202	Por For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.19 Approve Discharge of Supervisory Board Member Vishal Sikka for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.20 Approve Discharge of Supervisory Board Member Sibylle Wankel for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.21 Approve Discharge of Supervisory Board Member Thomas Wittig for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 4.22 Approve Discharge of Supervisory Board Member Werner Zierer for Fiscal Year 2022	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 5 Approve Remuneration Report	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 6 Ratify PricewaterhouseCoopers GmbH as Auditors for Fiscal Year 2023	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 7 Elect Kurt Bock to the Supervisory Board	Against	Yes
Bayerische Motoren Werke AG 05/11/2023 Germany 8.1 Approve Virtual-Only Shareholder Meetings Until 2025	For	No
Bayerische Motoren Werke AG 05/11/2023 Germany 8.2 Amend Articles Re: Participation of Supervisory Board Members in the Annual General M	Meeting by Means of Audio and Video Transmission For	No
Bio-UV Group SA 05/26/2023 France 6 Acknowledge End of Mandate of Patrice Morot as Alternate Auditor and Decision Not to		No
Bio-UV Group SA 05/26/2023 France 3 Approve Allocation of Income and Dividends of EUR 0.06 per Share	For	No
Bio-UV Group SA 05/26/2023 France 4 Approve Auditors' Special Report on Related-Party Transactions	Against	Yes
Bio-UV Group SA 05/26/2023 France 2 Approve Consolidated Financial Statements and Statutory Reports	For	No
Bio-UV Group SA 05/26/2023 France 1 Approve Financial Statements and Statutory Reports	For	No
Bio-UV Group SA 05/26/2023 France 13 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiari		No
Bio-UV Group SA 05/26/2023 France 8 Approve Remuneration of Directors in the Aggregate Amount of EUR 80,000	For	No
Bio-UV Group SA 05/26/2023 France 14 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delega		No
Bio-UV Group SA 05/26/2023 France 15 Authorize Capital Issuances for Use in Employee Stock Purchase Plans	For	No
Bio-UV Group SA 05/26/2023 France 11 Authorize Capitalization of Reserves of Up to EUR 5 Million for Bonus Issue or Increase i		No
Bio-UV Group SA 05/26/2023 France 10 Authorize Decrease in Share Capital via Cancellation of Repurchased Shares	For	No
Bio-UV Group SA 05/26/2023 France 17 Authorize Filing of Required Documents/Other Formalities	For	No
Bio-UV Group SA 05/26/2023 France 12 Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Ag		No
Bio-UV Group SA 05/26/2023 France 9 Authorize Repurchase of Up to 10 Percent of Issued Share Capital	For	No
Bio-LIV Group SA 05/26/2023 France 16 Authorize up to 3 Percent of Issued Capital for Use in Restricted Stock Plans Reserved for State Control of Section 1997 (1997) 1997 (19		Yes
Bio-UV Group SA 05/26/2023 France 7 Elect Stephanie La Beuze as Director	For	No
Bio-UV Group SA 05/26/2023 France 5 Renew Appointment of PricewaterhouseCoopers Audit as Auditor	For	No
BP Pic 04/27/2023 United Kingdom 1 Accept Financial Statements and Statutory Reports	For	No
BP Plc 04/27/2023 United Kingdom 2 Approve Remuneration Report	For	No
BP Plc 04/27/2023 United Kingdom 3 Approve Remuneration Policy	For	No
BP Plc 04/27/2023 United Kingdom 4 Re-elect Helge Lund as Director	For	No
BP Plc 04/27/2023 United Kingdom 5 Re-elect Bernard Looney as Director	For	No
BP Plc 04/27/2023 United Kingdom 6 Re-elect Murray Auchincloss as Director	For	No
	For	No
BP Pic 04/27/2023 United Kingdom 7 Re-elect Paula Reynolds as Director		No
BP Plc         04/27/2023         United Kingdom         7         Re-elect Paula Reynolds as Director           BP Plc         04/27/2023         United Kingdom         8         Re-elect Melody Meyer as Director	For	
BP Pic         04/27/2023         United Kingdom         7         Re-elect Paula Reynolds as Director           BP Pic         04/27/2023         United Kingdom         8         Re-elect Melody Meyer as Director           BP Pic         04/27/2023         United Kingdom         9         Re-elect Tushar Morzaria as Director	For	No
BP Pic         04/27/2023         United Kingdom         7         Re-elect Paula Reynolds as Director           BP Pic         04/27/2023         United Kingdom         8         Re-elect Melody Meyer as Director           BP Pic         04/27/2023         United Kingdom         9         Re-elect Tushar Morzaria as Director           BP Pic         04/27/2023         United Kingdom         10         Re-elect Sir John Sawers as Director	For For	No No
BP Pic         04/27/2023         United Kingdom         7         Re-elect Paula Reynolds as Director           BP Pic         04/27/2023         United Kingdom         8         Re-elect Melody Meyer as Director           BP Pic         04/27/2023         United Kingdom         9         Re-elect Tushar Morzaria as Director	For	No

BP Plc	04/27/2023	United Kingdom				No
BP Plc	04/27/2023	United Kingdom	14	Elect Amanda Blanc as Director	For	No
BP Plc	04/27/2023	United Kingdom	15	Elect Satish Pai as Director	For	No
BP Plc	04/27/2023	United Kingdom	16	Elect Hina Nagarajan as Director		No
BP Plc	04/27/2023	United Kingdom		Reappoint Deloitte LLP as Auditors		No
BP Plc	04/27/2023	United Kingdom				No
	04/27/2023	United Kingdom				No
BP Plc	04/27/2023	United Kingdom	20	Authorise Issue of Equity		No
	04/27/2023	United Kingdom				No
BP Plc	04/27/2023	United Kingdom	22	Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment		No
BP Plc	04/27/2023	United Kingdom				No
	04/27/2023	United Kingdom				No Yes
	04/27/2023	United Kingdom	1			
	06/23/2023 06/23/2023	France	2	Approve Financial Statements and Discharge Directors Approve Discharge of Chairman of the Board for his Mandate from January 1, 2022 until September 30, 2022		No No
Cabasse SA Cabasse SA	06/23/2023	France France	3			No No
Cabasse SA Cabasse SA	06/23/2023	France	4			No
Cabasse SA Cabasse SA	06/23/2023	France	5			Yes
	06/23/2023	France	6			Yes
	06/23/2023	France	7			Yes
	06/23/2023	France	8			Yes
Cabasse SA	06/23/2023	France	9		Against	Yes
	06/23/2023	France	10			Yes
	06/23/2023	France	11			Yes
Cabasse SA	06/23/2023	France	12			No
	06/23/2023		13			Yes
Cabasse SA	06/23/2023	France	14			Yes
	06/23/2023	France	15			No
Cabasse SA	06/23/2023	France	16	Authorize Decrease in Share Capital via Cancellation of Repurchased Shares		No
	06/23/2023	France	17			No
	07/24/2023	France	28		For	No
Diagnostic Medical Systems	07/24/2023	France	4			No
Diagnostic Medical Systems	07/24/2023	France	3		For	No
Diagnostic Medical Systems	07/24/2023	France	7		For	No
Diagnostic Medical Systems	07/24/2023	France	2	Approve Consolidated Financial Statements and Statutory Reports	For	No
Diagnostic Medical Systems	07/24/2023	France	5			No
Diagnostic Medical Systems	07/24/2023	France	1		For	No
	07/24/2023	France	16			Yes
Diagnostic Medical Systems	07/24/2023	France	19			Yes
	07/24/2023	France	18			Yes
	07/24/2023		6			No
Diagnostic Medical Systems	07/24/2023	France	8			Yes
	07/24/2023	France	21			Yes
Diagnostic Medical Systems	07/24/2023	France	23	Authorize Capital Increase of up to 10 Percent of Issued Capital for Contributions in Kind		No
	07/24/2023	France	17		Against	Yes
Diagnostic Medical Systems	07/24/2023	France	27	Authorize Capital Issuances for Use in Employee Stock Purchase Plans	For	No
	07/24/2023	France	20			No
Diagnostic Medical Systems	07/24/2023	France	13 29			No No
Diagnostic Medical Systems	07/24/2023	France	14	Authorize Filing of Required Documents/Other Formalities		
Diagnostic Medical Systems Diagnostic Medical Systems	07/24/2023	France			Against	Yes Yes
		Ferre				res
		France	15		Against	V
Diagnostic Medical Systems	07/24/2023	France	26	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital	Against Against	Yes
Diagnostic Medical Systems	07/24/2023 07/24/2023	France France	26 12	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital	Against Against Against	Yes
Diagnostic Medical Systems Diagnostic Medical Systems	07/24/2023 07/24/2023 07/24/2023	France France France	26 12 24	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans	Against Against Against Against	Yes Yes
Diagnostic Medical Systems Diagnostic Medical Systems Diagnostic Medical Systems	07/24/2023 07/24/2023 07/24/2023 07/24/2023	France France France France	26 12 24 25	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans	Against Against Against Against Against Against	Yes Yes Yes
Diagnostic Medical Systems Diagnostic Medical Systems Diagnostic Medical Systems Diagnostic Medical Systems	07/24/2023 07/24/2023 07/24/2023	France France France	26 12 24 25 10	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director	Against Against Against Against Against Against Against	Yes Yes
Diagnostic Medical Systems	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023	France France France France France France France	26 12 24 25 10 11	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Laurence Borie as Director	Against Against Against Against Against Against Against Against	Yes Yes Yes Yes Yes
Diagnostic Medical Systems	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023	France France France France France	26 12 24 25 10	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jaurence Borie as Director Reelect Samuel Sancerin as Director	Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes
Diagnostic Medical Systems	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023	France France France France France France France France France	26 12 24 25 10 11 9	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Reelect Samuel Sancerni as Director Reelect Samuel Sancerni as Director	Against Against Against Against Against Against Against Against For For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023	France	26 12 24 25 10 11	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Reelect Samuel Sancerni as Director Reelect Samuel Sancerni as Director	Against Against Against Against Against Against Against Against For For For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hitlino Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023	France France France France France France France France France USA	26 12 24 25 10 11 9 22 3	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Select Jean-Francois Gendron as Director Set Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raifty Named Executive Officers Compensation Elect Director Charlene T. Begley	Against Against Against Against Against Against Against Against For For For For For	Yes Yes Yes Yes Yes No No
Diagnostic Medical Systems Diagnostic Medical Sy	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023	France France France France France France France France France USA USA USA	26 12 24 25 10 11 9 22 3 1c	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Reelect Samuel Sancerni as Director Reelect Samuel Sancerni as Director Set Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Chrine T. Begley Elect Director Chrine Carr	Against Against Against Against Against Against Against Against For For For For For	Yes Yes Yes Yes Yes You No No No No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. Hilton Worldwide Holdings Inc. Hilton Worldwide Holdings Inc. Hilton Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023	France France France France France France France France USA USA	26 12 24 25 10 11 9 22 3 1c	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Reelect Samuel Sancerni as Director Selet Journel Sancerni as Director Sel Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christopher J. Nassetta	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No No No No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France France France France France France France France France USA USA USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1d 1a 1i 1h	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jauence Borie as Director Reelect Samuel Sancerni as Director Reelect Samuel Sancerni as Director Reelect Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raifly Named Executive Officers' Compensation Elect Director Chartene T. Begley Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No No No No No No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France France France France France France France France USA USA USA USA USA USA	26 12 24 25 10 11 9 22 3 1c 1d 1a 1i	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jauence Borie as Director Reelect Samuel Sancerni as Director Reelect Samuel Sancerni as Director Reelect Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raifly Named Executive Officers' Compensation Elect Director Chartene T. Begley Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta	Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hitton Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France France France France France France France France France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1h 1b	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Reelect Samuel Sancernia so Director Selet Josan-Francois Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Chris Carr Elect Director Chris Carr Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Christopher J. Smith Elect Director Jonathan D. Gray	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hitton Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France France France France France France France France France USA	26 12 24 25 10 11 11 9 22 3 1c 1c 1d 1a 1i 1h 1b 1g 1g	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Relect Samuel Sancerni as Director Set Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Douglas M. Steenland Elect Director Jought A. Smith Elect Director Joughthan D. Gray Elect Director Joughthan D. Gray Elect Director Melanie L. Healey	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France France France France France France France France France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1h 1b 1g 1g	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Reelect Samuel Sancernia as Director Selet Staurnes Bone as Director Self Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raitly Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christoner T. Begley Elect Director Christoner J. Nassetta Elect Director Christoner J. Nassetta Elect Director Elizabeth A. Smith Elect Director Elizabeth A. Smith Elect Director Loudin A. McHale Elect Director Jounthan D. Gray Elect Director Melanie L. Healey	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc.	07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023 05718/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1d 1d 1a 1i 1b 1b 1q 1e 1f 1f 2	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Elect Jean-Francois Gendron as Director Elect Laurence Borie as Director Reelect Samuel Sancerni as Director Selet Josan-Francois Gendron as Director Selet Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christoper J. Nassetta Elect Director Christoper J. Nassetta Elect Director Christoper J. Nassetta Elect Director Elizabeth A. Smith Elect Director Jonathan D. Gray Elect Director Jonathan D. Gray Elect Director Jonathan D. Gray Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France USA	26 12 24 25 10 11 19 22 3 1c 1d 1a 1i 1h 1b 1g 1e 1f 2	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Relect Samuel Sancerni as Director Set Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Charlene T. Begley Elect Director Chris Carr Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Joudith A. McHale Elect Director Indiana D. Gray Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Adopt Time-Bound Policy to Phase Out Underwriting and Lending for New Fossil Fuel Development	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JiHon Worldwide Holdings Inc.	07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 05718/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1d 1a 1i 1b 1b 1g 1e 1f 1g 26 6 3	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Elect Jean-Francois Gendrion as Director Relect Jean-Francois Gendrion as Director Reelect Samuel Sancerin as Director Sel Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christopen J. Nassetta Elect Director Christopen J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Jonathan D. Gray Elect Director Jonathan D. Gray Elect Director Aughtin A. McHale Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Adopt Time-Bound Policy to Phase Out Underwriting and Lending for New Fossil Fuel Development Advisory Vote on Say on Pay Frequency	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JiPhorgan Chase & Co. JiPMorgan Chase & Co. JiPMorgan Chase & Co. JiPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1c 1d 1a 1i 1h 1b 1g 1e 1e 1f 26 6 3 3 2 2	Authorize Issuance of Warrants (BSPCE) without Preemptive Richts Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Elect Jean-Francois Gendron as Director Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Set Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christopen J. Nassetta Elect Director Christopen J. Nassetta Elect Director Christopen J. Nassetta Elect Director Douglas M. Steenland Elect Director Jought M. Steenland Elect Director Jought A. Smith Elect Director Jought A. McHale Elect Director Melanie L. Healey Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote to Ratify Named Executive Officers' Compensation	Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JiPMorgan Chase & Co. JPMorgan Chase & Co. JPMorgan Chase & Co. JPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1d 1a 1i 1h 1b 1g 1e 1f 2 6 3 3 2 7	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Relect Samuel Sancernia as Director Sel Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christoper J. Nassetta Elect Director Jonathan D. Gray Elect Director Jonathan D. Gray Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote to Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote to Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote to Raymond E. Mabus, Jr. Radify Remond Public Responsibility Committee Charles Inter to Incube Animal Welfare	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023	France France France France France France France France France USA	26 12 24 25 10 11 11 9 22 3 1c 1c 1d 1a 1i 1b 1g 1e 1f 1g 2e 6 3 3 2 7	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Laurence Borie as Director Relect Samuel Sancerni as Director Selet Staurence Borie as Director Selet Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Joudin A. McHalle Elect Director Joudin A. McHalle Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Frequency Advisory Vote to Ratify Named Executive Officers' Compensation Amend Public Responsibility Committee Charler in Include Animal Welfare Disclose 2030 Absolute GRR Reduction Targets Associated with Lending and Underwriting	Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JiPMorgan Chase & Co. JPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/16/2023 05/16/2023 05/16/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1h 1b 1g 1e 1e 1f 2 6 3 2 7 7 12	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Self Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Chris Carr Elect Director Chris Carr Elect Director Christopher J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Lizabeth A. Smith Elect Director Alaythan D. Gray Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Adotor Time-Baymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Frequency Elect Director Responsibility Committee Charter to Include Animal Welfare Disclose 2030 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director Rick Gorsky Elect Director Rick Gorsky Elect Director Responsibility Committee Charter to Include Animal Welfare	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hitton Worldwide Holdings Inc. JPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1c 1d 1d 1a 1i 1b 1p 1g 1e 1f 1f 2 6 3 3 2 7 7 11 11 11 11 11 12 11 11 11 12 11 11 11	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Relect Samuel Sancerni as Director Relect Samuel Sancerni as Director Selet Journel Sancerni as Director Relect Samuel Sancerni as Director Relect Samuel Sancerni as Director Sel Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christoper J. Nassetta Elect Director Christoper J. Nassetta Elect Director Christoper J. Nassetta Elect Director Douglas M. Steenland Elect Director Clizabeth A. Smith Elect Director Jounathan D. Gray Elect Director Jounathan D. Gray Elect Director Malanie L. Healey Elect Director Malanie L. Healey Elect Director Malanie L. Healey Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote to Raymond E. Mabus, Jr. Advisory Vote to Raymond E. Mabus, Jr. Advisory Vote to Raymond E. Mabus, Gray Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote to Ratify Named Executive Officers' Compensation Amend Public Responsibility Committee Charter to Include Animal Welfare Disclose 2000 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director Alics Gorsky	Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. Jilton Worldw	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1h 1b 1g 1e 1f 2 6 3 3 2 7 7 12 11 11 11	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Self Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christoner J. Nassetta Elect Director Christoner J. Nassetta Elect Director Elizabeth A. Smith Elect Director Elizabeth A. Smith Elect Director Elizabeth A. Smith Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Adolo Time-Bayon Planse Officers' Compensation Advisory Vote to Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote to Ratify Named Executive Officers' Compensation Amend Public Responsibility Committee Charter to Include Animal Welfare Disclose 2030 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director Ratify Gendre Executive Officers' Compensation Amend Public Responsibility Committee Charter to Include Animal Welfare Disclose 2030 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director Alicia Boler Davis Elect Director Alicia Boler Davis	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JPMorgan Chase & Co.	07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 05718/2023	France France France France France France France France France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1b 1b 1g 1e 1f 1g 26 6 3 2 7 7 12 1h 1e 1f 1d	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Set Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratify Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christoper J. Nassetta Elect Director Christoper J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Jonathan D. Gray Elect Director Jonathan D. Gray Elect Director Audith A. McHale Elect Director Raymond E. Mabus, Jr. Ratify Ernst & Young LLP as Auditors Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Committee Charler to Include Animal Welfare Disclose 2030 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director Alicia Boler Davis Elect Director James S. Crown	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JiHon Worldwide Holdings Inc. JiHon Worldwide Holdings Inc. JiHon Worldwide Holdings Inc. JiPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1c 1d 1a 1i 1b 1b 1g 1e 2 6 3 2 7 7 12 1h 1e 1e 1f 1d 1a 1i 1i 1d	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francols Gendron as Director Elect Jean-Francols Gendron as Director Reelect Samuel Sancenia as Director Self Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raifty Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christoner J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Jounglas M. Steenland Elect Director Jounglas M. Steenland Elect Director Jounglas M. Steenland Elect Director Raymond E. Mabus, Jr. Raifty Ernst & Young LLP as Auditors Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Frequency Advisory Vote to Raifty Named Executive Officers' Compensation Answer Vote on Say on Pay Frequency Advisory Vote to Raifty Named Executive Officers' Compensation Amend Public Responsibility Committee Charter to Include Animal Welfare Disclose 2030 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director Alex Gorsky Elect Director James S. Crown	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JPMorgan Chase & Co.	07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/18/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1d 1a 1i 1b 1b 1g 1e 1f 2 6 3 3 2 7 12 1h 1e 1f 1d 1d 1a 1i 1d 1d 1a	Authorize Issuance of Warrants (BSPCE) without Preemptive Richits Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Repurchase of Up to 10 Percent of Issued Stare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Relect Jean-Francois Gendron as Director Relect Isamuel Sancenia as Director Sel Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raiffy Mamed Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Chris Carr Elect Director Chris Carr Elect Director Chris Carr Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Jounth A. McHale Elect Director Jounth A. McHale Elect Director Allona D. Gray Elect Director Raymond E. Mabus, Jr. Raiffy Ernst & Young LLP as Auditors Advisory Vote on Say on Pay Frequency Advisory Vote to Raiffy Named Executive Officers' Compensation Elect Director Alicia Boler Davis Elect Director James S. Grown Elect Director James S. Grown Elect Director James S. Grown Elect Director James S. Bammann Elect Director Lalaes B. Bammann Elect Director Lalaes B. Bammann Elect Director Lalaes B. Bammann	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1b 1g 1e 1f 2 6 3 3 2 7 7 12 1h 1e 1f 1d	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Laurence Borie as Director Reelect Samuel Sancerni as Director Self Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raftly Named Executive Officers' Compensation Elect Director Christoner T. Begley Elect Director Christoner J. Nassetta Elect Director Christoner J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Joudith A. McHale Elect Director Maymond E. Mabus, Jr. Raftly Ernst & Young LIP as Auditors Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Frequency Advisory Vote to Raftly Named Executive Officers' Compensation Anneand Public Responsibility Committee Charter to Include Animal Welfare Disclose 2030 Absolute GRI Reduction Targets Associated with Lending and Underwriting Elect Director Alex Gorsky Elect Director Alex Gorsky Elect Director Alex Gorsky Elect Director Judic Bammann Elect Director Judic Bammann Elect Director Meliole H. Okale Director Alex Gorsky Elect Director Judic Bammann Elect Director Meliole H. Okale Director Alex Gorsky Elect Director Judic Bammann Elect Director Meliole Hobson Elect Director Judic Bammann Elect Director Meliole Hobson	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JPMorgan Chase & Co.	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1h 1b 1g 1e 1f 2 6 3 2 7 7 12 1h 1e 1f 1d 1a 1i 1i 1d 1a 1i	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize Reputchase of Up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Elect Jean-Francios Gendron as Director Elect Laurence Borie as Director Elect Jauence Borie as Director Reelect Samuel Sancerin as Director Sel Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Raftiv Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Charlene T. Begley Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Christopher J. Smith Elect Director Onoglas M. Steenland Elect Director Graymond E. Mebus Jr. Raftiy Ernst & Young LL P. as Auditors Adopt Time-Bound Policy to Phase Out Underwriting and Lending for New Fossil Fuel Development Adopt Time-Bound Policy to Phase Out Underwriting and Lending for New Fossil Fuel Development Adopt Time-Bound Policy to Phase Out Underwriting and Lending and Underwriting Elect Director Alex Rosny Work to Raftiy Named Executive Officers' Compensation Amend Public Responsibility Committee Charter to Include Animal Welfare Disclose 2030 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director James B. Crown Elect Director James B. Crown Elect Director James S. Crown Elect Director Helanic A. Neal	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. JPMorgan Chase & Co.	07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 07724/2023 05/18/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1d 1a 1i 1b 1b 1g 1e 1f 1f 2 6 3 3 2 7 7 12 1h 1d 1a 1i 1i 1t	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Elect Laurence Borie as Director Reelect Samuel Sancerni as Director Self Total Limit for Capital Increase to Result from All Issuance Requests at EUR 50 Million Advisory Vote to Ratfiv Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Christopher J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Joudith A. McHale Elect Director Melanie L. Healey Elect Director Melanie L. Healey Elect Director Joudith A. McHale Elect Director Joudith A. McHale Elect Director Joudith A. McHale Elect Director Melanie L. Healey Elect Director Melanie L. Resulted Melanie L. Healey Elect Director Melanie L. Resulted Melanie L. Healey Elect Director Melanie L. Healey Elect Director Melanie E. Healey Elect Director Journal Policy to Phase Out Underwriting and Lending for New Fossil Fuel Development Advisory Vote on Say on Pay Frequency Advisory Vote to Ratfy Named Executive Officers' Compensation Amend Public Responsibility Committee Charter to Include Animal Welfare Elect Director James S. Crown Elect Director James Dimon Elect Director James S. Crown Elect Director James S. Crown Elect Director Mellody Hobson Elect Director Mellody Hobson	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No
Diagnostic Medical Systems Hilton Worldwide Holdings Inc. Jilton Wo	07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 07/24/2023 05/18/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023 05/16/2023	France USA	26 12 24 25 10 11 11 9 22 3 1c 1d 1a 1i 1h 1b 1g 1e 1f 2 6 3 2 7 7 12 1h 1e 1f 1d 1a 1i 1i 1d 1a 1i	Authorize Issuance of Warrants (BSPCE) without Preemptive Rights Reserved for Specific Beneficiaries, up to 10 Percent of Issued Capital Authorize up to 10 Percent of Issued Sare Capital Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock Plans Authorize up to 10 Percent of Issued Capital for Use in Stock Option Plans Elect Jean-Francois Gendron as Director Reelect Samuel Sancerni as Director Reelect Samuel Sancerni as Director Reelect Samuel Sancerni as Director Reelect Total Limit for Capital Increase to Result from Ail Issuance Requests at EUR 50 Million Advisory Vote to Ratily Named Executive Officers' Compensation Elect Director Charlene T. Begley Elect Director Charlene T. Begley Elect Director Christopher J. Nassetta Elect Director Douglas M. Steenland Elect Director Douglas M. Steenland Elect Director Jonathan D. Gray Elect Director Jonathan D. Gray Elect Director Melanie L. Healey Elect Director Melanie L. Healey Elect Director Alond Policy to Phase Out Underwriting and Lending for New Fossil Fuel Development Advisory Vote to Ratify Named Executive Officers' Compensation Annend Public Responsibility Committee Charler to Include Animal Welfare Disclose 2030 Absolute GHG Reduction Targets Associated with Lending and Underwriting Elect Director Alica Boler Davis Elect Director Stephen B. Burke Elect Director Stephen B. Burke	Against Against Against Against Against Against Against Against Against For	Yes Yes Yes Yes Yes No

JPMorgan Chase & Co.	05/16/2023	USA	11	Elect Director Virginia M. Rometty	Against	Yes
JPMorgan Chase & Co.	05/16/2023	USA	4	Ratify PricewaterhouseCoopers LLP as Auditors	For	No
JPMorgan Chase & Co.	05/16/2023	USA	8		For	Yes
JPMorgan Chase & Co.	05/16/2023	USA	9	Report on Climate Transition Plan Describing Efforts to Align Financing Activities with GHG Targets	For	Yes
JPMorgan Chase & Co.	05/16/2023	USA	11	Report on Publical Expenditures Congruence		Yes
JPMorgan Chase & Co.	05/16/2023	USA	10			No.
JPMorgan Chase & Co.	05/16/2023	USA	5		For	Yes
			2			
Mercedes-Benz Group AG	05/03/2023	Germany				No
Mercedes-Benz Group AG	05/03/2023	Germany	3		For	No
Mercedes-Benz Group AG	05/03/2023	Germany	4			No
Mercedes-Benz Group AG	05/03/2023	Germany	5.1	Ratify KPMG AG as Auditors for Fiscal Year 2023	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	5.2	Ratify PricewaterhouseCoopers GmbH as Auditors for the 2024 Interim Financial Statements until the 2024 AGM	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	5.3	Training is necessarily to the first		No
Mercedes-Benz Group AG	05/03/2023	Germany	6	Elect Stefan Pierer to the Supervisory Board	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	7	Approve Remuneration of Supervisory Board	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	8	Approve Remuneration Policy	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	9	Approve Remuneration Report	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	10	Approve Creation of EUR 1 Billion Pool of Authorized Capital with or without Exclusion of Preemptive Rights	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	11	Approve Virtual-Only Shareholder Meetings Until 2025	For	No
Mercedes-Benz Group AG	05/03/2023	Germany	12		For	No
Northland Power Inc.	05/18/2023	Canada	1	Elect Director John W. Brace	For	No
Northland Power Inc.	05/18/2023	Canada	1	Elect Director Linda L. Bertoldi	For	No
Northland Power Inc.	05/18/2023	Canada	3			Yes
Northland Power Inc.	05/18/2023	Canada	4		For	No.
	05/10/2023		5	Elect Director Kevin Glass		
	05/18/2023	Canada	,	Elect Director Russell Goodman		No No
Northland Power Inc.	05/18/2023	Canada	6	Elect Director Keith Halbert		No
Northland Power Inc.	05/18/2023	Canada	7		Withhold	Yes
Northland Power Inc.	05/18/2023	Canada	8			Yes
Northland Power Inc.	05/18/2023	Canada	9	Elect Director Eckhardt Ruemmler	Withhold	Yes
Northland Power Inc.	05/18/2023	Canada	10			No
Northland Power Inc.	05/18/2023	Canada	11	Advisory Vote on Executive Compensation Approach	For	No
Oracle Corporation	11/15/2023	USA	3	Advisory Vote on Say on Pay Frequency	One Year	No
Oracle Corporation	11/15/2023	USA	2	Advisory Vote to Ratify Named Executive Officers' Compensation	Against	Yes
	11/15/2023	USA	4	Amend Omnibus Stock Plan	Against	Yes
Oracle Corporation	11/15/2023	USA	1.1	Flect Director Awo Ablo	Withhold	Yes
	11/15/2023	USA	1.5	Elect Director Bruce R. Chizen	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.11	Elect Director Charles W. Moorman		Yes
Oracle Corporation	11/15/2023	USA	16	Elect Director George H. Conrades	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.9	Elect Director Jeffrey O. Henley	Withhold	Yes
	11/15/2023	USA	1.2			Yes
	11/15/2023	USA	1.7	Elect Director Lawrence J. Ellison	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.12	Elect Director Leon E. Panetta	Withhold	Yes
	11/15/2023	USA	1.3	Elect Director Michael J. Boskin	Withhold	Yes
	11/15/2023	USA	1.14	Elect Director Naomi O. Seligman	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.10	Elect Director Renee J. James	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.8	Elect Director Rona A. Fairhead	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.4	Elect Director Safra A. Catz	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.15	Elect Director Vishal Sikka	Withhold	Yes
Oracle Corporation	11/15/2023	USA	1.13	Elect Director William G. Parrett	Withhold	Yes
Oracle Corporation	11/15/2023	USA	5	Ratify Ernst & Young LLP as Auditors	For	No
Oracle Corporation		USA		Report on Median and Adjusted Gender/Racial Pay Gaps		Yes
	11/15/2023		6		For	
Oracle Corporation	11/15/2023	USA	7			Yes
Oracle Corporation SOGECLAIR SA	11/15/2023	USA USA	7	Require Independent Board Chair	For	Yes
SOGECLAIR SA	11/15/2023 05/11/2023	USA USA France	7 24	Require Independent Board Chair  Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds	For Against	Yes Yes
SOGECLAIR SA SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023	USA USA France France	7 24 23	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term	For Against For	Yes Yes No
SOGECLAIR SA SOGECLAIR SA SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023	USA USA France France France	7 24 23 3	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share	For Against For For	Yes Yes No No
SOGECLAIR SA SOGECLAIR SA SOGECLAIR SA SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA France France France France France	7 24 23 3 4	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions	For Against For For Against	Yes Yes No No Yes
SOGECLAIR SA SOGECLAIR SA SOGECLAIR SA SOGECLAIR SA SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA France France France France France France France	7 24 23 3 4 5	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO	For Against For For Against For	Yes Yes No No Yes No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA France France France France France France France France France	7 24 23 3 4 5 6	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report	For Against For For Against For For	Yes Yes No No No No No No No No No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA France	7 24 23 3 4 5 6	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Composition Report	For Against For For Against For For For	Yes Yes No No No No No Yes No No No No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA France	7 24 23 3 4 5 6 2	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Listing of the Company Shares on Euronext Growth Paris	For Against For For Against For For For	Yes Yes No No No No No Yes No No No No No No No No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 5 6 6 2	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Financial Statements and Statutory Reports	For Against For For Against For	Yes Ves No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Compensation Report Approve Compensation Report Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Inancial Statements and Statutory Reports	For Against For For Against For For For For For For Against	Yes Yes No
SOGECLAIR SA	11/16/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 5 6 6 2 11 11 11 16	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Fhilippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Isauance of Equity or Equity-Linked Securities For Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160,000	For Against For Against For Against For For For For For Against Against Against Against	Yes   Yes   No   No   No   No   No   No   No   N
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 6 18 8	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Philippe Robardey-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Compensation Report Approve Delishing from Euronext Paris and Usting of the Company Shares on Euronext Growth Paris Approve Delishing from Euronext Paris and Usting of the Company Shares on Euronext Growth Paris Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160,000 Approve Removeration Policy of CEO	For Against For For Against For For For For For Against For For For For For For Against Against For	Yes No
SOGECLAIR SA	11/16/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 5 6 6 2 11 11 1 1 16 18 8 7 7	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Financial Statements and Islain of the Company Shares on Euronext Growth Paris Approve Financial Statements and Statutory Reports Approve Islanacial Statements and Statutory Reports Approve Islaunce of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Remuneration Policy of CEO Approve Remuneration Policy of Chairman of the Board	For Against For For Against For For For For For Against For For For For For For Against Against For	Yes No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 6 18 8 7 7 9 9	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEYS, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of CEO Approve Remuneration Policy of CEO Approve Remuneration Policy of Officerors	For Against For For Against For For For Against For For For For For For Against Against Against For For Against For For For Against For For Against For	Yes No No No Yes No
SOGECLAIR SA	11/16/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 11 11 1 1 16 18 8 7 7	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEYS, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of CEO Approve Remuneration Policy of CEO Approve Remuneration Policy of Officerors	For Against For For Against For For For Against For For For For For For Against Against Against For For Against For For For Against For For Against For	Yes No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 6 18 8 7 7 9 9	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Sensors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Islating of the Company Shares on Euronext Growth Paris Approve Financial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Islamace of Equity of Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Islamace of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of Chairman of the Board Southers Reserved to Increase Scapital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18	For Against For For Against For	Yes No No No Yes No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 5 6 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Feport on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Directors Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights	For Against For For Against For	Yes No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Sensors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Insurance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of Ceo Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Orbairman of the Board Approve Remuneration Policy of Policetors Authorize Soard to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Increase Capital Increase of up to 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights	For Against For Against For For For For For For For For Against	Yes Ves No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation Final Report Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Plansacial Statements and Statutory Reports Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Orbairman of the Board Approve Remu	For Against For For For Against For For Against For For Against	Yes Ves No
SOGECLAIR SA	11/15/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023 05/11/2023	USA USA USA France	7 24 23 3 4 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Istatutory Reports Approve Pinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Invancial Statements and Statutory Reports Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of CEC  Approve Remuneration Policy of CEC  Approve Remuneration Policy of Directors Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Increase Capital in the Event of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent Per Year of Issued Capital Pursuant to Issue Authority Without Preemptive Rights Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans	For Against For Against For For For For For For For For Against	Yes No
SOGECLAIR SA	11/15/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Islating of the Company Shares on Euronext Growth Paris Approve Inancial Statements and Islating of the Company Shares on Euronext Growth Paris Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEYS, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Detectors Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Capital Increase of up to 10 Percent Per Year of Issued Capital Iror Contributions in Kind Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans	For Against For	Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA France	7 24 23 3 4 5 6 6 2 11 1 16 18 8 7 9 19 19 17 20 22 13 12 25	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Seport on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from EuronexY Paris and Listing of the Company Shares on Euronext Growth Paris Approve Delisting from EuronexY Paris and Listing of the Company Shares on Euronext Growth Paris Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 1 Million Approve Remuneration Policy of CEO Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Directors Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Capital Increase of up to 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Increase in Par Value Authorize Capital Increase of Up to EUR 1 Million for Borus Is	For Against For	Yes No
SOGECLAIR SA	111/15/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Pinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Inancial Statements and Statutory Reports Approve Remuneration of Equity of Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 1 Million Approve Remuneration Policy of Collection Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Originator Originator Statements Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Increase Capital in the Event of Issued Capital Irvariant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent Per Year of Issued Capital Torrason of United Programs of United States Stock Purchase Plans Authorize Capital Issuences for Use in Employee Stock Purchase Plans Authorize Capital States of Reserves of Up to EUR 1 Million for Bonus Issue or Increase in Par Value Authorize Filing of Required Documents/Other Formalities Authorize States and Capital Irvariants of Capital Irvariants of Teach of S	For Against For For For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA France	7 24 23 3 4 5 6 6 2 11 1 1 16 18 8 7 9 19 19 17 20 22 13 12 25 14	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Delisting from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Pinancial Statements and Statutory Reports Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 180,000 Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Directors Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Engital Suances for Use in Employee Stock Purchase Plans Authorize Salvalia Issuances for Use in Employee Stock Purchase Plans Authorize Salvalia Issuances for Use in Employee Stock Purchase Plans Authorize Salvalia Issuances of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 1 Million Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount	For Against For For For Against For For For For Against For For Against Against Against Against For Against For Against For Against For Against For Against Against Against Against For	Yes Yes No
SOGECLAIR SA	111/15/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 11 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Insurance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 160.000 Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Originator of the Board Approve Remuneration Policy of Under Insurance State	For Against For For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Shareholding Disclosure Thresholds Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consploated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Insurance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 180,000 Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Directors Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital To Contributions in Kind Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capitalization of Reserves of Up to EUR 1 Million for Bonus Issue or Increase in Par Value Authorize Equital Issuances of Use to Tuse in Employee Stock Purchase Plans Authorize Equital Issuances of Use Increase of Shares Authorize Equital Increase of Share Capital in Cancellation of Repurchased Shares Authorize Equital Increase of Share Capital in Cancellation of Repurchased Shares Authorize Bourchase Of Use Increase of Sauthorites wi	For Against For	Yes Yes No
SOGECLAIR SA	11/15/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 2 11 11 11 11 16 18 8 7 9 19 17 20 22 21 13 12 25 14 15 15 11 11 11 11 11 11 11 11 11 11 11	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Senors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Insurance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEYS, up to Aggregate Nominal Amount of EUR 160,000 Approve Remuneration Policy of CEO Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Undertons Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Increase Capital Increase of up to 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Increase in Par Value Authorize Capital Increase of the Servers of Up to 10 Percent of Issued Shares Authorize Edinal Zerope Share Shares Authorize Edinal Zerope Shares of Up to 10 Percent Percent of Issued Shares Authorize Edinal Zerope Shares of Up to 10 Percent Percent of Issued Shares Authorize Edinal Zerope Shares of Up to 10 Percent Percent of Issued Shares Authorize Shares Shares Shares Shares Authorize Shares Shares Shares Shares Shares Shares Sha	For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Islain of the Company Shares on Euronext Growth Paris Approve Prinancial Statements and Statutory Reports Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing from Euronext Growth Paris Approve Remuneration Policy of Celliparis of Every E	For Against For	Yes Yes No
SOGECLAIR SA TESIS, Inc. TESIS, Inc.	11/15/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 11 1 16 18 8 7 9 19 19 17 20 22 13 12 25 14 15 10 21 3 2	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 1 Million Approve Remuneration Policy of CEU Approve Remuneration Policy of Discloris Authorize Sand to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Increase Capital in the Event of Issued Capital Fore Approximation of the State Prince for 10 Percent Per Year of Issued Capital Princesor of Up to 10 Percent of Issued Capital fore Approximation of Up to 10 Percent of Issued Capital Fore Approximation of Princesor of Up to 10 Percent of Issued Shares Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 1 Million Authorize Repurchase of Up to 10 Percent of Issued Share Capital Set Total Limit for Capital Increase to Result from Issuance Re	For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Islain of the Company Shares on Euronext Growth Paris Approve Prinancial Statements and Statutory Reports Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Islain from Euronext Paris and Listing from Euronext Growth Paris Approve Remuneration Policy of Celliparis of Every E	For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 11 1 16 18 8 7 9 19 19 17 20 22 13 12 25 14 15 10 21 3 2	Require Independent Board Chair Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Shareholding Disclosure Thresholds Amend Article 12 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation for Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Insurance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEY'S, up to Aggregate Nominal Amount of EUR 180,000 Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Undersons Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Increase Capital in the Event of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital for Increase in Nare Capital Increase of up to 10 Percent of Issued Capital for Increase in Par Value Authorize Capital Issuances of Up to 10 Increase Increase Increase in Par Value Authorize Capital Issuances of Up to 10 Increase Increase Increase in Par Value Authorize Fining of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 1 Million Authorize Issuance of Equity or Equity-Linked Securities without	For Against For	Yes Yes No
SOGECLAIR SA Tesia, Inc. Tesia, Inc. Tesia, Inc.	111/5/2023 05/11/2023	USA USA USA USA France	7 24 23 3 4 5 6 6 2 111 11 11 11 18 8 7 9 19 17 20 22 13 12 25 14 15 10 21 3 2 1.1	Require Independent Board Chair Amend Article 13 of Bylaws Re: Cansors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Conspensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Designing from Euronext Paris and Listing of the Company Shares on Euronext Growth Paris Approve Prinancial Statements and Statutory Reports Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 180,000 Approve Remuneration Policy of CEO Approve Remuneration Policy of CEO Approve Remuneration Policy of Directors Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 1 Million Authorize Repurchase of Up to 10 Percent Per Very Capital Securities with Preemptive Rights up to Aggregate Nominal A	For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA France	7 24 23 3 4 5 6 6 2 11 1 1 16 18 8 7 9 19 19 19 11 20 21 13 12 25 14 15 10 21 3 2 1.1 1.3	Require Independent Board Chair Amend Article 12 of Blywars Re: Cansors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Remuneration of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Remuneration Policy of CEO Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Original Private Placements of State St	For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA  USA  France  USA  USA  USA  USA  USA  USA  USA  US	7 24 23 3 4 5 6 6 2 11 11 11 16 18 8 7 9 17 20 22 13 12 22 13 12 25 14 15 10 21 3 2 1.1 3 1.2 4	Require Independent Board Chair Amend Article 13 of Bylaws Re: Censors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Insurance of Equity to Equity-Linked Securities or Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Issuance of Equity or Equity-Linked Securities Reserved for KEYS, up to Aggregate Nominal Amount of EUR 180,000 Approve Remuneration Policy of CEO Approve Remuneration Policy of Directors Approve Remuneration Policy of Directors Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 14-16 and 18 Authorize Board to Set Issue Price for 10 Percent Per Year of Issued Capital Pursuant to Issue Authority without Preemptive Rights Authorize Capital Increase of up to 10 Percent of Issued Capital Increase of up to 10 Percent of Issued Capital Increase of up to 10 Percent of Issued Scapital for Contributions in Kind Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 1 Million Authorize Repurchase of Up to 10 Percent of Issued Share Capital Securities with Preemp	For Against For	Yes Yes No
SOGECLAIR SA	111/5/2023 05/11/2023	USA USA USA USA USA France Fra	7 24 23 3 4 5 6 2 11 11 11 11 18 8 7 9 19 17 20 22 13 12 25 14 15 10 21 11 11 11 11 11 11 11 11 11 11 11 11	Require Independent Board Chair Amend Article 12 of Blywars Re: Cansors Length of Term Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Allocation of Income and Dividends of EUR 0.90 per Share Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation of Philippe Robardey, Chairman and CEO Approve Compensation Report Approve Consolidated Financial Statements and Statutory Reports Approve Prinancial Statements and Statutory Reports Approve Financial Statements and Statutory Reports Approve Remuneration of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 1 Million Approve Remuneration Policy of CEO Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Chairman of the Board Approve Remuneration Policy of Original Private Placements of State St	For Against For	Yes Yes No

TotalEnergies SE						
TotalEnergies SE	05/26/2023	France	3	Approve Allocation of Income and Dividends of EUR 3.81 per Share	For	No
TotalEnergies SE	05/26/2023	France	4	Authorize Repurchase of Up to 10 Percent of Issued Share Capital	For	No
TotalEnergies SE	05/26/2023	France	5	Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions	For	No
TotalEnergies SE	05/26/2023	France	6	Reelect Marie-Christine Coisne-Roquette as Director	Against	Yes
TotalEnergies SE	05/26/2023	France	7	Reelect Mark Cutifani as Director	Against	Yes
TotalEnergies SE	05/26/2023	France	8	Elect Dierk Paskert as Director	For	No
TotalEnergies SE	05/26/2023	France	9	Elect Anelise Lara as Director	For	No
TotalEnergies SE	05/26/2023	France	10	Approve Compensation Report of Corporate Officers	For	No
TotalEnergies SE	05/26/2023	France	11	Approve Remuneration Policy of Directors; Approve Remuneration of Directors in the Aggregate Amount of EUR 1.95 Million	For	No
TotalEnergies SE	05/26/2023	France	12	Approve Compensation of Patrick Pouyanne, Chairman and CEO	For	No
TotalEnergies SE	05/26/2023	France	13	Approve Remuneration Policy of Chairman and CEO	For	No
TotalEnergies SE	05/26/2023	France	14	Approve the Company's Sustainable Development and Energy Transition Plan	Against	Yes
TotalEnergies SE	05/26/2023	France	15	Authorize up to 1 Percent of Issued Capital for Use in Restricted Stock Plans		No
TotalEnergies SE	05/26/2023	France	16	Authorize Capital Issuances for Use in Employee Stock Purchase Plans	For	No
TotalEnergies SE	05/26/2023	France	17	Remove Double-Voting Rights for Long-Term Registered Shareholders and Amend Article 18 of Bylaws Accordingly	For	No
TotalEnergies SE	05/26/2023	France	A	Align Targets for Indirect Scope 3 Emissions with the Paris Climate Agreement (Advisory)	For	Yes
Veolia Environnement SA	04/27/2023	France	1		For	No
Veolia Environnement SA	04/27/2023	France	2	Approve Consolidated Financial Statements and Statutory Reports	For	No
Veolia Environnement SA	04/27/2023	France	3	Approve Non-Deductible Expenses	For	No
Veolia Environnement SA	04/27/2023	France	4	Approve Allocation of Income and Dividends of EUR 1.12 per Share	For	No
Veolia Environnement SA	04/27/2023	France	5	Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New Transactions	For	No
Veolia Environnement SA	04/27/2023	France	6	Reelect Maryse Aulagnon as Director	For	No
Veolia Environnement SA	04/27/2023	France	7	Elect Olivier Andries as Director	For	No
Veolia Environnement SA	04/27/2023	France	8	Elect Veronique Bedague-Hamilius as Director	For	No
Veolia Environnement SA	04/27/2023	France	9	Elect Francisco Reynes as Director	For	No
Veolia Environnement SA	04/27/2023	France	10	Renew Appointment of Ernst & Young et Autres as Auditor	For	No
Veolia Environnement SA	04/27/2023	France	11	Approve Compensation of Antoine Frerot, Chairman and CEO from January 1, 2022 until June 30, 2022	For	No
Veolia Environnement SA	04/27/2023	France	12	Approve Compensation of Antoine Frerot, Chairman of the Board from July 1, 2022 until December 31, 2022	For	No
Veolia Environnement SA	04/27/2023	France	13	Approve Compensation of Estelle Brachlianoff, CEO from July 1, 2022 until December 31, 2022	For	No
Veolia Environnement SA	04/27/2023	France	14	Approve Compensation Report of Corporate Officers	For	No
Veolia Environnement SA	04/27/2023	France	15	Approve Remuneration Policy of Chairman of the Board	For	No
Veolia Environnement SA	04/27/2023	France	16		For	No
Veolia Environnement SA	04/27/2023	France	17		For	No
	04/27/2023	France	18	Authorize Repurchase of Up to 10 Percent of Issued Share Capital	For	No
Veolia Environnement SA	04/27/2023	France	19	Authorize Capital Issuances for Use in Employee Stock Purchase Plans	For	No
Veolia Environnement SA	04/27/2023	France	20	Authorize Capital Issuances for Use in Employee Stock Purchase Plans Reserved for Employees and Corporate Officers of International Subsidiaries	For	No
	04/27/2023	France	21	Authorize up to 0.35 Percent of Issued Capital for Use in Restricted Stock Plans Reserved for Employees and Corporate Officers With Performance Conditions Attached	For	Nο
Veolia Environnement SA	04/27/2023	France	22	Amend Article 15 of Bylaws Re: Corporate Purpose	Against	Yes
Veolia Environnement SA	04/27/2023	France	23	Authorize Filing of Required Documents/Other Formalities	For	No
Vogo SA	06/12/2023	France	6	Approve Auditors' Special Report on Related-Party Transactions	For	Nο
	06/12/2023	France	2	Approve Consolidated Financial Statements and Statutory Reports	For	No
Vogo SA	06/12/2023	France	1	Approve Financial Statements and Discharge Directors	For	No
Vogo SA						
	106/12/2023	France	15	Approve Issuance of 99.369 Warrants (BSA) Reserved for Specific Beneficiaries	Against	Yes
	06/12/2023		15 16	Approve Issuance of 99,369 Warrants (BSA) Reserved for Specific Beneficiaries  Approve Issuance of 99,369 Warrants (BSCPCF) Resenged for Specific Beneficiaries	Against	
Vogo SA	06/12/2023	France	16	Approve Issuance of 99,369 Warrants (BSPCE) Reserved for Specific Beneficiaries	Against	Yes
Vogo SA Vogo SA				Approve Issuance of 99,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000		
Vogo SA Vogo SA Vogo SA	06/12/2023 06/12/2023 04/19/2023	France France	16 12 1	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75	Against Against For	Yes Yes No
Vogo SA Vogo SA Vogo SA Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023	France France France France	16 12	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000	Against Against	Yes Yes
Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023 06/12/2023	France France France France France	16 12 1 1	Approve Issuance of 99,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses	Against Against For Against For	Yes Yes No Yes No
Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023	France France France France France France France	16 12 1 13 3	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account	Against Against For Against	Yes Yes No Yes No No
Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France France France France France	16 12 1 13 3 5	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account	Against Against For Against For For For	Yes Yes No Yes No
Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France	16 12 1 13 3 5	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Treatment of Losses Approve Treatment of Losses Approve Treatment of Losses Approve Treatment of Losses	Against Against For Against For For Against For Against	Yes Yes No Yes No No No No
Vogo SA Vogo SA	06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 04/19/2023	France France France France France France France France France	16 12 1 13 3 5 4 14 3	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Treatment of Losses Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans	Against Against For Against For	Yes Yes No Ves No Ves No No No No No No No
Voqo SA Voqo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 04/19/2023 06/12/2023	France	16 12 1 13 3 5 5 4 14 14 3	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans	Against Against For Against For For Against For Against	Yes Yes No Yes No Yes
Vogo SA Vogo SA	06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 04/19/2023	France	16 12 1 13 3 5 4 14 3	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Non-Deductible Expenses Approve Treamfer from Carry Forward Account to Issuance Premium Account Approve Treatment of Losses Approve Treatment of Losses Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances Capital in Encellation of Repurchased Shares	Against Against For Against For	Yes Yes No Yes No Yes No
Voqo SA Voqo SA	06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 04/19/2023	France	16 12 1 1 13 3 5 4 4 14 3 3 17 20 5	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares	Against Against For Against For For For Against For	Yes Yes No No Yes No
Voqo SA Voqo SA	06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France	16 12 1 1 13 3 5 4 4 14 3 17 20	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Treatment of Losses Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities	Against Against For Against For	Yes Yes No No Yes No
Vogo SA Vogo SA	06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France	16 12 1 1 13 3 5 4 4 14 3 17 20 5	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances of Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities	Against Against For Against For	Yes Yes No No Yes No
Vogo SA	06/12/2023 04/19/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 04/19/2023 04/19/2023 06/12/2023 04/19/2023 04/19/2023	France	16 12 1 1 13 3 5 4 4 14 3 17 20 5 5 21	Approve Issuance of 93.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities withour Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000	Against Against For Against For	Yes Yes No
Vogo SA Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France	16 12 1 1 13 3 5 4 14 14 3 17 20 5 5 21	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Piling of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Susuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuances of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000	Against Against For Against For Against For For For For For For Against For Against For Against Against For For For For For For For For Against Against Against Against	Yes Yes No No Yes No Yes No No No No Yes Yes
Voqo SA	06/12/2023 04/19/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France	16 12 1 1 13 3 5 4 14 14 3 17 20 5 21 10 11 11 9	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Poercase in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Isling of Required Documents/Other Formalities Authorize Isling of Required Documents/Other Formalities Authorize Isling of Required Documents/Other Formalities Authorize Islance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Islance of Equity or Equity-Linked Securities with up Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Repurchase of Up to 10 Percent of Issued Share Capital	Against Against For Against For	Yes Yes No No Yes No No No No No No No No No Yes No No No Yes Yes Yes Yes Yes
Vogo SA	06/12/2023 06/19/2023 04/19/2023 04/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France	16 12 1 13 3 5 4 14 14 3 17 20 5 21 10 11 9	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Treatment of Losses Approve Treatment of Losses Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase Location of Registered Office to 895 rue de la Vieille Poste, Parc Majoria-Pompignane, Immeuble La Lona, 34000 Montpellier and Amend Article 4 of Bylaws Accordingly	Against Against For Against For For For For For For For For For Against For For Against Against For	Yes Yes No
Vogo SA	06/12/2023 06/19/2023 04/19/2023 06/19/2023 06/19/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023 06/12/2023	France	16 12 1 1 13 3 5 4 14 14 3 7 7	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Shares for Use in Restricted Stock Plans Raitly Change Location of Registered Office to 895 rue de la Vieille Poste, Parc	Against Against For Against For	Yes Yes No Yes No Yes Yes Yes Yes Yes Yes Yes
Voqo SA	06/12/2023 04/19/2023 04/19/2023 06/12/2023	France	16 12 1 13 3 5 4 14 14 3 17 20 5 21 10 11 9 18	Approve Issuance of 93.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Sustance of Use in Employee Stock Purchase Plans Authorize Premium Account Issuance Account Issuance Account Issuance Account Issuance Account Issuance Iss	Against Against For Against For For For For For For For For For Against For	Yes Yes No Yes No
Vogo SA	06/12/2023 06/12/2023 04/19/2023 04/19/2023 06/12/2023	France	16 12 1 13 3 5 4 14 14 3 17 20 5 5 21 10 11 9 18 8 7	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities withou Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000  Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Right	Against Against For Against For	Yes Yes No No Yes No
Voqo SA	06/12/2023 04/19/2023 04/19/2023 06/12/2023	France	16 12 11 13 3 5 4 14 14 3 17 20 5 5 21 10 11 9 18 8 7 7 19	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Eling of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 149,054 Shares for Use in Restricted Stock Plans Ratify Change Location of Registered Office to 895 rue de la Vieille Poste, Parc Majoria-Pompignane, Immeuble La Lona, 34000 Montpellier and Amend Article 4 of Bylaws Accordingly Reselect Veronique Puyau as Director Set Total Limit for Capital Increase to Result from Issuance Requests Under Items	Against Against For Against For For For For For For For Against For	Yes Yes Yes No
Vogo SA	06/12/2023 06/12/2023 04/19/2023 04/19/2023 06/12/2023	France	16 12 1 13 3 5 4 14 14 3 17 20 5 21 10 11 19 11 18 8 7 19 2 4	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Pling of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000  Set Total Limit for Capi	Against Against For Against For For For For For For For Against For	Yes Yes No Yes No
Vogo SA	06/12/2023 04/19/2023 04/19/2023 06/12/2023	France	16 12 1 1 13 3 5 4 14 14 3 17 20 5 5 21 10 11 19 18 8 7 19 2 4 4	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Eling of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 149,054 Shares for Use in Restricted Stock Plans Ratify Change Location of Registered Office to 895 rue de la Vieille Poste, Parc Majoria-Pompignane, Immeuble La Lona, 34000 Montpellier and Amend Article 4 of Bylaws Accordingly Reselect Veronique Puyau as Director Set Total Limit for Capital Increase to Result from Issuance Requests Under Items	Against Against For Against For Against For Against For For For For Against For	Yes Yes No
Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023	France	16 12 1 1 13 3 5 4 4 14 14 3 17 20 5 21 10 11 11 9 18 8 7 7 19 2 4 4 3 3 5 5	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000  Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Agg	Against Against For Against For	Yes Yes Yes No
Vogo SA	06/12/2023 04/19/2023 04/19/2023 04/19/2023 06/12/2023	France	16 12 1 1 13 3 5 4 14 14 3 17 20 5 21 10 11 9 18 8 7 7 19 2 4 4 3 5 5 10 11 11 11 11 11 11 11 11 11 11 11 11	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize North Repurchase of Reput Percent of Issued Share Capital Authorize North Reput Percent Percent Reput Pe	Against Against For Against For	Yes Yes No Yes No
Vogo SA	06/12/2023 06/12/2023	France	16 12 1 1 13 3 5 4 4 14 14 3 17 20 5 10 10 11 11 9 18 8 7 19 2 4 4 4 3 3 16 16 16 16 16 16 17	Approve Issuance of 93,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize up to 149,054 Shares for Use in Restricted Stock Plans Ratify Change Location of Registered Office to 895 rue de la Vieille Poste, Parc Majoria-Pompignane, Immeuble La Lona, 34000 Montpellier and Amend Article 4 of Bylaws Accordingly Reelect Veronique Puyau as Director Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 10-16 and 18 at EUR 500,000 Subject to Approval of Item 1 Above, Elect ABEO as Director Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Frequency Increase	Against Against For Against For	Yes Yes Yes Yes No
Vogo SA	06/12/2023 06/12/2023 04/19/2023 04/19/2023 06/12/2023	France USA USA USA USA	16 12 11 13 3 5 4 4 14 14 3 3 17 20 5 5 21 10 11 19 18 8 7 7 19 2 4 4 3 5 11 10 11 11 11 11 11 11 11 11 11 11 11	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000  Authorize Issuance of E	Against Against For Against For	Yes Yes No
Vogo SA	06/12/2023 06/12/2023 04/19/2023 06/12/2023	France USA USA USA USA USA	16 12 1 13 3 5 4 14 14 3 17 20 5 21 10 11 19 9 18 8 7 19 2 4 4 4 3 3 5 10 11 11 11 11 11 11 11 11 11 11 11 11	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize up to 149,054 Shares for Use in Restricted Stock Plans Ratify Change Location of Registered Office to 895 rue de la Vieille Poste, Parc Majoria-Pompignane, Immeuble La Lona, 34000 Montpellier and Amend Article 4 of Bylaws Accordingly Reelect Veronique Puyau as Director Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 10-16 and 18 at EUR 500,000 Subject to Approval of Item 1 Above, Elect ABEO as Director Advisory Vote on Say on Pay Frequency Advisory Vote on Say on Pay Frequency Increase Increase in Result Formal Elect Director Janes C. Fish, Jr. Elect Director Janes	Against Against Against For Against For For For For Against For	Yes Yes No
Vogo SA	06/12/2023 06/12/2023 04/19/2023 04/19/2023 06/12/2023	France Fr	16 12 11 13 3 5 4 4 14 14 3 3 17 20 5 5 21 10 11 19 18 8 7 19 22 4 4 3 3 5 10 10 11 11 11 11 11 11 11 11 11 11 11	Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Agg	Against Against For Against For	Yes Yes Yes No No Yes No
Vogo SA Vogo S	06/12/2023 06/12/2023 04/19/2023 04/19/2023 06/12/2023	France	16 12 1 13 3 5 4 14 14 3 17 20 5 21 10 11 9 18 8 7 19 2 4 4 4 3 3 5 5 10 11 11 11 11 11	Approve Issuance of 99.369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities or Private Placements, up to Aggregate Nominal Amount of EUR 108.695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108.695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500.000 Approve Nome Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500.000 Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500.000 Authorize Repurchase of Up to 10 Percent of Issued Share Capital Authorize up to 149.054 Shares for Use in Restricted Stock Plans Raity Change Location of Registered Office to 855 rue de la Vieille Poste, Parc Majoria-Pompignane, Immeuble La Lona, 34000 Montpellier and Amend Article 4 of Bylaws Accordingly Relect Veronique Puyau as Director Advisory Vote on Say on Pay Frequency Advisory Vote to Raity Capital State Capital Related Stock Plans Elect Direct	Against Against Against For Against For For For For Against For	Yes Yes No
Vogo SA Vogo S	06/12/2023 06/12/2023 04/19/2023 04/19/2023 04/19/2023 06/12/2023	France Fr	16 12 11 13 3 5 4 4 14 14 3 17 20 5 5 21 10 11 19 18 8 7 19 22 4 4 3 5 5 1c 1c 1a 1b 1h 1e 1i	Approve Issuance of 99,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities or Private Placements, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities Agreement A	Against Against For Against For	Yes Yes Yes Yes No
Vogo SA Vogo S	06/12/2023 06/12/2023 04/19/2023 04/19/2023 06/12/2023	France USA USA USA USA USA USA USA USA USA	16 12 1 1 13 3 5 4 4 14 3 17 20 5 21 10 11 9 18 8 7 7 19 2 4 4 3 5 5 10 11 11 11 11 11 11 11 11 11 11 11 11	Approve Issuance of 99,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity Teauly-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Agpurchase of Up to 10 Percent of Issued Share Capital Authorize up to 149,045 Shares for Use in Restricted Stock Plans Ratty Change Location of Repistered Office to 895 rue de la Vieiller Poste, Parc Majoria-Pompignane, Immeuble La Lona, 34000 Montpellier and Amend Article 4 of Bylaws Accordingly Releict Veronique Puyau as Director Advisory Vote to Say on Pay Frequency Advisory Vote to Say on Pay Frequency Advisory Vote to Ratty Rama and Zabove, Eleit ABEO as Director Advisory Vote to Ratty Capital Research Result from Issuance Requests Under Items 10-16 and 18 at EUR 500,000 Subject to Approval of Item 1 Abo	Against   Against   Against   Against   Against   For   Fo	Yes Yes No
Vogo SA Vogo S	06/12/2023 06/12/2023 04/19/2023 06/12/2023 06/09/2023 05/09/2023 05/09/2023 05/09/2023 05/09/2023 05/09/2023	France Fr	16 12 11 13 3 5 4 4 14 14 3 17 20 5 5 21 10 11 19 18 8 7 19 22 4 4 3 5 5 1c 1c 1a 1b 1h 1e 1i	Approve Issuance of 99,369 Warrants (BSPCE) Reserved for Specific Beneficiaries Approve Issuance of Equity or Equity-Linked Securities or Private Placements, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 108,695.75 Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 500,000 Approve Non-Deductible Expenses Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account to Issuance Premium Account Approve Transfer from Carry Forward Account of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Above Under Items 10-13 Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Capital Issuances for Use in Employee Stock Purchase Plans Authorize Decrease in Share Capital via Cancellation of Repurchased Shares Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Filing of Required Documents/Other Formalities Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 500,000 Authorize Issuance of Equity or Equity-Linked Securities Agreement A	Against Against For Against For	Yes Yes Yes Yes No